The drug pricing and controlling regulator has fixed the ceiling price of 509 essential medicines bringing down the prices of 127 drugs by over 40 percent, informed the minister today.
The National Pharmaceutical Pricing Authority (NPPA) has has fixed the ceiling price of 509 essential medicines out of 680 medicines (628 net medicines) contained in the Schedule-1 of DPCO 2013, Minister of State for Chemicals and Fertilizers Hansraj Gangaram Ahir told the Lok Sabha.
Out of 509 drugs, 127 essential medicines have seen 40% decline prices while prices of 34 other drugs have come down in the range of 35 to 40%, the minister said. About 30 drugs’ prices have come down in the range of 30-35 percent, 57 drugs in 25-30 percent and 65 drugs saw a reduction between 20-25 percent, the minister said.
Apart from this, the price of 44 drugs has gone down by 15-20 percent, 10-15 percent in case of 55 drugs, between 5-10 percent for 46 drugs and up to 5 percent in case of 51 medicines, Ahir said.
Prices of all drugs incorporated in the First Schedule to DPCO, 2013 are monitored and controlled by the NPPA.
Functions of National Pharmaceutical Pricing Authority (NPPA) include:
- To implement and enforce the provisions of the Drugs (Prices Control) Order in accordance with the powers delegated to it.
- to deal with all legal matters arising out of the decisions of the Authority;
- to monitor the availability of drugs, identify shortages, if any, and to take remedial steps;
- to collect/ maintain data on production, exports and imports, market share of individual companies, profitability of companies etc, for bulk drugs and formulations;
- to undertake and/ or sponsor relevant studies in respect of pricing of drugs/ pharmaceuticals;
- to recruit/ appoint the officers and other staff members of the Authority, as per rules and procedures laid down by the Government;
- to render advice to the Central Government on changes/ revisions in the drug policy;
- to render assistance to the Central Government in the parliamentary matters relating to the drug pricing.